<DOC>
	<DOCNO>NCT01666600</DOCNO>
	<brief_summary>Patients glioblastoma first second progression fail standard treatment must include radiochemotherapy temozolomide candidate reirradiation include trial . In phase I part minimal tolerate dose ( MTD ) BIBF 1120 combination radiotherapy investigate . Subjects phase II randomise receive reirradiation alone reirradiation + 2 x MTD BIBF1120 .</brief_summary>
	<brief_title>NOA-12 : BIBF1120 R-RT Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Male female patient recurrence / progression glioblastoma either eligible tumour resection macroscopic residual tumour resection recurrence Diagnosis glioblastoma must prove histologically progress must document MRI . MRI image must older 2 week first dosing/start RT Not two prior therapy regimens include one two resection , one two chemotherapy ( one temozolomide contain concomitant radiotherapy ) one radiotherapy ( RT ) brain tumour Previous irradiation therapy primary tumour maximal dose 60 Gy ; least 8 month since end preirradiation Candidate reirradiation recurrent tumour visible MRIT1 ( Gd ) large diameter measure 1 cm 5 cm Informed consent Age ≥ 18 year , smoke nonsmoking , ethnic origin Karnofsky performance index ( KPI ) ≥ 60 % Neutrophile count &gt; 1500/μl / Platelet count &gt; 80.000/μl /Haemoglobin &gt; 10 g/dl / Serum creatinine &lt; 1.5fold upper normal range / Bilirubin , AST ALT &lt; 2,5fold upper normal range unless attribute anticonvulsant / Alkaline phosphatase &lt; 2,5fold upper normal range Adequate contraception If steroid , stable decrease treatment steroid within 5 day treatment start More one RT brain , prior first radiotherapy 60 Gy Cumulative total dose optical chiasm &gt; 54 Gy 2 Gy/fraction , α/β=2 Prior treatment bevacizumab , iodine seed and/or brachytherapy Unable undergo MRI Past medical history disease poor prognosis accord judgement Investigator , e.g . severe coronary heart disease , severe diabetes , immune deficiency , residual deficit stroke , severe mental retardation HIV hepatitis infection Pregnancy breast feeding Treatment within clinical trial parallel treatment phase current study within 30 day inclusion Known coronary artery disease , significant cardiac arrhythmia severe congestive heart failure ( NYHA class III IV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>